Clinical Report: Comparative Analysis of Oliceridine and Sufentanil for Postoperative Pain Management

Overview

This study utilized machine learning to compare the efficacy and safety of Oliceridine and Sufentanil in postoperative pain management for burn skin grafting. Findings suggest that while both opioids have similar analgesic profiles, Oliceridine is associated with a significantly lower risk of postoperative nausea and vomiting (PONV).

Background

Postoperative pain management in burn surgery is critical due to the severe pain associated with skin grafting procedures. Traditional opioids like Sufentanil can lead to significant opioid-related adverse events, particularly PONV, which complicates recovery. Oliceridine, a biased μ-opioid agonist, presents a potential alternative with a more favorable safety profile, warranting investigation in this high-risk population.

Data Highlights

Key Findings

• Oliceridine and Sufentanil demonstrated comparable analgesic efficacy in burn skin grafting patients.
• The XGBoost model for efficacy had an AUC of 0.843, indicating strong predictive capability.
• PONV risk was significantly lower with Oliceridine compared to Sufentanil, particularly in female patients.
• The study utilized SHAP analysis to clarify the contributions of various predictors to analgesic outcomes.
• Machine learning models outperformed traditional logistic regression in predicting PONV.

Clinical Implications

The findings suggest that Oliceridine may be a safer alternative to Sufentanil for managing postoperative pain in burn patients, particularly in reducing the risk of PONV. Clinicians should consider the use of Oliceridine in multimodal analgesic strategies to enhance patient recovery and minimize adverse effects.

Conclusion

This study highlights the potential of Oliceridine in postoperative pain management for burn patients, offering similar analgesic effects to Sufentanil with a reduced risk of PONV. Further prospective studies are needed to validate these findings.

Related Resources & Content

1. American Burn Association Guidelines on the Management of Acute Pain in the Adult Burn Patient: A Review of the Literature, a Compilation of Expert Opinion, and Next Steps - PMC
2. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy - PMC
3. Efficacy and safety of oliceridine in daytime hysteroscopic polypectomy: a randomized, double-blind, single-center controlled trial
4. Reflections on: Comparing Intraperitoneal Dexmedetomidine and Ropivacaine for Managing Postoperative Pain Following Laparoscopic Sleeve Gastrectomy: Insights from a Double-Blind, Randomized, Placebo-Controlled Study
5. Comparative Effects of Opioid and Non-Opioid Analgesics on Postoperative Pain, Quality of Life, and Outcomes Following Ventral Hernia Repair
6. Comparative Study of Intrathecal Versus Intravenous Morphine for Postoperative Pain Management Following Hepatectomy: A Randomized Controlled Trial
7. DailyMed - DSUVIA- sufentanil tablet
8. American Burn Association Guidelines on the Management of Acute Pain in the Adult Burn Patient: A Review of the Literature, a Compilation of Expert Opinion, and Next Steps - PMC
9. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy - PMC